Quadrant Capital Group’s Celldex Therapeutics CLDX Stock Holding History

Quadrant Capital Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-160	Closed	-$5.08K	–	1502
2026 Q1	$5.08K	Hold	160	–	–	﹤0.01%	2350
2025 Q4	$4.35K	Hold	160	–	–	﹤0.01%	2410
2025 Q3	$4.14K	Buy	+160	New	+$3.71K	﹤0.01%	2354
2025 Q2	–	Sell	-334	Closed	-$6.06K	–	1594
2025 Q1	$6.06K	Buy	334 +267	+399%	+$5.97K	﹤0.01%	2320
2024 Q4	$1.69K	Buy	+67	New	+$1.82K	﹤0.01%	2516
2022 Q3	–	Sell	-132	Closed	-$4K	–	2653
2022 Q2	$4K	Buy	+132	New	+$3.83K	﹤0.01%	2022
2016 Q1	–	Sell	-25	Closed	-$5K	–	1827
2015 Q4	$5K	Buy	+25	New	+$5.45K	﹤0.01%	1077

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's CLDX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 160 shares — an estimated $5.08K sold.

Quadrant Capital Group first reported a position in CLDX in Q4 2015 and held it in 7 quarters. The position peaked at $6.06K in Q1 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Quadrant Capital Group reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 160 Celldex Therapeutics shares in Q2 2026, an estimated $5.08K.
Quadrant Capital Group first reported a position in Celldex Therapeutics in Q4 2015 and held it in 7 quarters.
Quadrant Capital Group's Celldex Therapeutics position peaked at $6.06K in Q1 2025.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.